There are no data regarding overdosage with atidarsagene autotemcel.
Atidarsagene autotemcel, sold under the brand name Libmeldy, is a gene therapy comprising genetically modified autologous CD34+ enriched hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene.L45191
Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic leukodystrophy (MLD).L45196 It was granted FDA approval under the brand name Lenmeldy in March 2024.L50256
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Elvitegravir | The therapeutic efficacy of Atidarsagene autotemcel can be decreased when used in combination with Elvitegravir. |
| Fostemsavir | The therapeutic efficacy of Atidarsagene autotemcel can be decreased when used in combination with Fostemsavir. |
| Ibalizumab | The therapeutic efficacy of Atidarsagene autotemcel can be decreased when used in combination with Ibalizumab. |